GB9918760D0 - Topical treatment - Google Patents

Topical treatment

Info

Publication number
GB9918760D0
GB9918760D0 GBGB9918760.1A GB9918760A GB9918760D0 GB 9918760 D0 GB9918760 D0 GB 9918760D0 GB 9918760 A GB9918760 A GB 9918760A GB 9918760 D0 GB9918760 D0 GB 9918760D0
Authority
GB
United Kingdom
Prior art keywords
topical treatment
topical
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9918760.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Priority to GBGB9918760.1A priority Critical patent/GB9918760D0/en
Publication of GB9918760D0 publication Critical patent/GB9918760D0/en
Priority to CA002378445A priority patent/CA2378445A1/en
Priority to PCT/GB2000/003032 priority patent/WO2001010427A2/en
Priority to AU63064/00A priority patent/AU6306400A/en
Priority to JP2001514947A priority patent/JP2003506405A/en
Priority to EP00949799A priority patent/EP1202723A2/en
Priority to IL14789100A priority patent/IL147891A0/en
Priority to ZA200200795A priority patent/ZA200200795B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9918760.1A 1999-08-09 1999-08-09 Topical treatment Ceased GB9918760D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB9918760.1A GB9918760D0 (en) 1999-08-09 1999-08-09 Topical treatment
CA002378445A CA2378445A1 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders
PCT/GB2000/003032 WO2001010427A2 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders
AU63064/00A AU6306400A (en) 1999-08-09 2000-08-07 Topical use of anti-muscarinic agents
JP2001514947A JP2003506405A (en) 1999-08-09 2000-08-07 Topical use of antimuscarinics
EP00949799A EP1202723A2 (en) 1999-08-09 2000-08-07 Use of anti-muscarinic agents for treating skin disorders
IL14789100A IL147891A0 (en) 1999-08-09 2000-08-07 Topical use of anti-muscarnic agents
ZA200200795A ZA200200795B (en) 1999-08-09 2002-01-29 Use of anti-muscarinic agents for treating skin disorders.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918760.1A GB9918760D0 (en) 1999-08-09 1999-08-09 Topical treatment

Publications (1)

Publication Number Publication Date
GB9918760D0 true GB9918760D0 (en) 1999-10-13

Family

ID=10858850

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9918760.1A Ceased GB9918760D0 (en) 1999-08-09 1999-08-09 Topical treatment

Country Status (8)

Country Link
EP (1) EP1202723A2 (en)
JP (1) JP2003506405A (en)
AU (1) AU6306400A (en)
CA (1) CA2378445A1 (en)
GB (1) GB9918760D0 (en)
IL (1) IL147891A0 (en)
WO (1) WO2001010427A2 (en)
ZA (1) ZA200200795B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302458A4 (en) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd Ester derivatives
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
DE102004016179A1 (en) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Compounds for the treatment of proliferative processes
WO2006054312A1 (en) * 2004-11-16 2006-05-26 Munisekhar Medasani Ammonium compounds for treating psoriasis and eczema
PL2098248T3 (en) * 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases
GB0611240D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2009068876A1 (en) * 2007-11-30 2009-06-04 Summit Corporation Plc Compositions for the treatment of skin disorders
WO2009150408A2 (en) * 2008-06-13 2009-12-17 Summit Corporation Plc Topical antimuscarinic formulations
JP6114841B2 (en) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． Glycopyrrolate salt
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2016173817A1 (en) 2015-04-28 2016-11-03 Unilever Plc N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same
MX368097B (en) 2015-04-28 2019-09-19 Unilever Nv N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same.
CN112730821B (en) * 2019-10-14 2024-04-09 泰州医药城国科化物生物医药科技有限公司 Method for analyzing long-acting property of receptor antagonist
CN110898227A (en) * 2019-11-04 2020-03-24 上海交通大学医学院附属瑞金医院卢湾分院 Combined medicine for treating psoriasis and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine

Also Published As

Publication number Publication date
CA2378445A1 (en) 2001-02-15
WO2001010427A2 (en) 2001-02-15
IL147891A0 (en) 2002-08-14
EP1202723A2 (en) 2002-05-08
ZA200200795B (en) 2003-03-26
AU6306400A (en) 2001-03-05
JP2003506405A (en) 2003-02-18
WO2001010427A3 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
HK1200316A1 (en) Therapeutic microfoams
AU7859800A (en) Topical nasal treatment
HK1050840A1 (en) Topical skin composition
GB9930570D0 (en) Therapy
GB9918760D0 (en) Topical treatment
GB9925136D0 (en) Novel treatment
GB9907243D0 (en) Therapy
IL144186A0 (en) Novel treatment
GB9911802D0 (en) Therapeutic combination
GB9911803D0 (en) Therapeutic combination
GB9911804D0 (en) Therapeutic combination
GB9919904D0 (en) Dressing
GB9924664D0 (en) Topical treatment assembly
GB9911238D0 (en) Therapeutic use
GB9815497D0 (en) Treatment
GB9818524D0 (en) Inorgasmia treatment
GB0206401D0 (en) Side effects treatment
GB9908993D0 (en) Treatment
GB9828550D0 (en) Treatment
GB9920787D0 (en) Novel treatment
GB9916655D0 (en) Novel treatment
GB9920788D0 (en) Novel treatment
GB9909650D0 (en) Novel treatment
GB9924713D0 (en) Therapy
GB9921063D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)